Tags : Facilities

Biosimilars M&A

WuXi Biologics to Acquire Pfizer’s Biologics Manufacturing Facilities in China

Shots: WuXi Biologics signs an equity agreement with Pfizer to acquire its state-of-the-art biologics manufacturing facilities along with its labor force in Hangzhou, China. The transaction is expected to close in H1’21 The agreement will boost WuXi Biologics’ commercial DS & DP capabilities to address surging manufacturing demands The state-of-the-art 50,000 m2 facilities include DS […]Read More